# Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer

> **NCT00079872** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 120 (—)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00079872
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 120 (—)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079872, "Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00079872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*